nach oben

Neurological Sciences

Erschienen in:

01.05.2012 | CONTROVERSIES IN PROPHYLAXIS

Controversies in migraine: monotherapy

verfasst von: Domenico D’Amico

Erschienen in: Neurological Sciences | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Migraine patients with frequent and severe headaches need prophylaxis. The most used approach is monotherapy, i.e. one of the available preventive compounds is prescribed to the patient, testing its efficacy and tolerability during a treatment period of some months. Some clinicians use to add a second (or even a third) preventive compound to improve the effects of pharmacological prophylaxis, using an approach that can be defined as polytherapy. In this paper, the main advantages of monotherapy are briefly reviewed, taking into account several aspects: published evidence on polytherapy; the possibility to evaluate the adverse events of the prescribed treatment and to assess its real efficacy; the possibility of addressing different patient’s needs, particularly the treatment of comorbidities and the development of an effective patient–physician communication.

Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657PubMedCrossRef

Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23:519–527PubMedCrossRef

Dueland AN, Leira R, Burke TA, Hillyer EV, Bolge S (2004) The impact of migraine on work, family, and leisure among young women—a multinational study. Curr Med Res Opin 20:1595–1604PubMedCrossRef

Leonardi M, Raggi A, Bussone G, D’Amico D (2010) Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache 50(10):1576–1586PubMedCrossRef

Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andrée C (2011) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. doi:10.1111/j.1468-1331

Silberstein SD, For the US Headache Consortium (2000) Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standars Subcommittee of the American Academy of Neurology. Neurology 55:754–762PubMedCrossRef

Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM (2000) Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. http://www.aan.com/professionals/practice/pdfs/gl0090.pdf. Accessed 20 Jan 2012

D’Amico D, Lanteri-Minet M (2006) Migraine preventive therapy: selection of appropriate patients and general principles of management. Expert Rev Neurother 6:1147–1157PubMedCrossRef

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343–349

10.

Evers S (2008) Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 9(15):2565–2573PubMedCrossRef

11.

D’Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4(6):1155–1167PubMedCrossRef

12.

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS, European Federation of Neurological Societies (2009) EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol 16(9):968–981PubMedCrossRef

13.

Rapoport A, Mauskop A, Diener HC, Schwalen S, Pfeil J (2006) Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 46(7):1151–1160PubMedCrossRef

14.

Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J, TOPMAT-MIG-303 Investigators Group (2007) Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 6(12):1054–1062PubMedCrossRef

15.

Krymchantowski AV, Bigal ME (2006) Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Rev Neurother 6(3):283–289PubMedCrossRef

16.

Pascual J, Leira R, Láinez JM (2003) Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23:961–962PubMedCrossRef

17.

Krymchantowski AV, Hampshire F (2004) Polytherapy in migraine prevention. Clinical experience with the combination of a tricyclic antidepressant plus a calcium channel blocker. Headache 44:499–500

18.

Pascual J, Rivas MT, Leira R (2007) Testing the combination betablocker plus topiramate in refractory migraine. Acta Neurol Scand 115:81–83PubMedCrossRef

19.

Luo N, Di W, Zhang A, Wang Y, Ding M, Qi W, Zhu Y, Massing MW, Fang Y (2012) A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 13(1):80–86PubMedCrossRef

20.

Bordini CA, Arruda MA, Cicciarelli MC, Speciali JG (1997) Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiaquiatr 55:536–541CrossRef

21.

Domingues RB, Silva AL, Domingues SA, Aquino CC, Kuster GW (2009) A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr 67(4):973–977PubMedCrossRef

22.

Keskinbora K, Aydinli I (2007) A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 110(10):979–984CrossRef

23.

Krymchantowski AV, da Cunha Jevoux C, Bigal ME (2012) Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain 13(1):53–59PubMedCrossRef

24.

Krymchantowski AV, da Cunha Jevoux C (2012) Low-dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy. Headache 52(1):129–132PubMedCrossRef

25.

Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB (2007) Pharmacological approaches to managing migraine and associated comorbidities—clinical considerations for monotherapy versus polytherapy. Headache 47:585–599PubMedCrossRef

26.

D’Amico D, Curone M, Tullo V, Proietti Cecchini A, Mea E, Bussone G (2011) Polytherapy for the prophylaxis of chronic migraine: an Italian survey. Neurol Sci 32(Suppl 1):S185–S188PubMedCrossRef

27.

Peterlin BL, Calhoun AH, Siegel S, Mathew NT (2008) Rational combination therapy in refractory migraine. Headache 48(6):805–819PubMedCrossRef

Titel: Controversies in migraine: monotherapy
verfasst von: Domenico D’Amico
Publikationsdatum: 01.05.2012
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe Sonderheft 1/2012
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-012-1059-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

New prospects in the taxonomic classification of primary headaches

Migraine and depression: bidirectional co-morbidities?

Polytherapy for migraine prophylaxis

Migraine and depression comorbidity: antidepressant options

Functional neuroimaging in migraine: usefulness for the clinical neurologist

Migraine: risk factor and comorbidity